摘要
目的:观察拜糖平联合西格列汀治疗餐后血糖控制不佳2型社区糖尿病的临床疗效。方法:抽选2013年3月-2014年5月本社区健康服务中心管理的2型社区糖尿病患者168例,分为联合组(n=84)和对照组(n=84)。对照组给予拜糖平餐前吞服,观察组在此基础上给予西格列汀口服治疗,均治疗6个月,比较两组患者FPG、2 h PG及Hb A1c水平,总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)水平,对比治疗疗效及不良反应率。结果:联合组总有效率为90.5%高于对照组的78.6%,差异有统计学意义(P<0.05)。两组患者用药3个月后2 h PG、Hb A1c水平较用药前降低,用药后较用药3个月时进一步降低,差异均有统计学意义(P<0.05);联合组用药3个月及用药后2 h PG、Hb A1c水平均低于对照组,差异均有统计学意义(P<0.05)。两组患者用药后TC、LDL水平均下降,与用药前比较差异均有统计学意义(P<0.05)。联合组不良反应率为9.5%,与对照组的10.7%比较差异无统计学意义(P>0.05)。结论:拜糖平联合西格列汀用于治疗餐后血糖控制不佳2型社区糖尿病,能有效降低患者2 h PG、Hb A1c水平,安全性高。
Objective：To observe the clinical curative effect of Acarbose combined with Sitagliptin in thetreatment of poor control of postprandial blood glucose with type 2 community diabetes.Method：A total of 168 patients with type 2 diabetes treated in the hospital of the community from March 2013 to May 2014 were divided into the combined group（n=84） and the control group（n=84）.The control group were given Acarbose swallowed before meals.Based on this,the observation group was treated with oral Sitagliptin.Both of the two group were treated for 6 months.The levels of FPG,2 h PG,Hb A1 c,total cholesterol（TC）,triglyceride（TG）,low density lipoprotein（LDL） and high density lipoprotein（HDL） were compared between the two groups.The curative effect and the incidence of adverse reactions were also compared.Result：The total effective rate of the combined group（90.5%） was significantly higher than that of the control group（78.6%）（P〈0.05）.The levels of 2 h PG and Hb A1 c in the two groups 3 months of drug use later were significantly lower than those before the treatment and those after drug use were further lower than those 3 months of drug use later（P〈0.05）.The levels of 2 h PG and Hb A1 c in the combined group after drug use and 3 months of drug use later were significantly lower than those in the control group（P〈0.05）.After drug use,the levels of TC and LDL in the two groups decreased significantly and compared with those before drug use,the differences were statistically significant（P〈0.05）.The difference in the incidence rate of adverse reactions in the combined group（9.5%） and the control group（10.7%） were not statistically significant（P〉0.05）.Conclusion：Acarbose combined with Sitagliptin in the treatment of poor control of postprandial blood glucose with type 2 community diabetes can effectively reduce the levels of 2 h PG and Hb A1 c,with high security.
出处
《中国医学创新》
CAS
2016年第11期125-128,共4页
Medical Innovation of China
基金
深圳市龙岗区科技发展资金医疗卫生(扶持类)项目(YLWS20140608105207145)
关键词
拜糖平
西格列汀
餐后血糖
社区糖尿病
Acarbose
Sitagliptin
Postprandial blood glucose
Community diabetes
